Custom Semaglutide CAS 910463-68-2 - Top China Suppliers and Factory for Effective Weight Management Solutions Manufacturers, Pricelist

,

Semaglutide is a leading glucagon-like peptide-1 (GLP-receptor agonist that has been clinically demonstrated to support effective weight management. By imitating the action of the natural hormone GLP-1, semaglutide is instrumental in regulating appetite and blood sugar levels. This innovative treatment not only facilitates weight loss but also enhances metabolic health, making it an ideal choice for individuals looking to transform their lifestyles. As a trusted product from China, our semaglutide is sourced directly from reliable suppliers and manufactured in state-of-the-art factories, ensuring quality and effectiveness for weight loss and metabolic improvement.

,

Product Description

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of drugs that have been clinically proven to be effective in helping individuals manage their weight. By mimicking the effects of the natural hormone GLP-1, semaglutide plays a vital role in regulating appetite and blood sugar levels. This innovative approach not only aids in weight loss, but also improves metabolic health, making it a comprehensive solution for those seeking to change their lifestyle.

Mechanism & Efficacy

Semaglutide is a GLP-1 receptor agonist that regulates blood glucose by stimulating insulin secretion and inhibiting glucagon release. It is commonly used in clinical research for type 2 diabetes management, weight management, and obesity-related studies.

Dosage & Clinical Use

Semaglutide (marketed as Wegovy®/Ozempic®) is administered by once‑weekly subcutaneous injection. Common dosing protocols for obesity and weight management range from 0.25 mg up to 2.4 mg weekly, with gradual titration based on tolerance and therapeutic goals. A new higher 7.2 mg weekly dose has been approved in some regions to enhance weight‑loss efficacy in clinical settings.

Patent & Intellectual Property

Semaglutide is protected by a broad patent portfolio covering compositions, formulations, and therapeutic uses. Key U.S. patents include:
  • US11318191 – GLP‑1 compositions and uses, expires Feb 17, 2041
  • US11478533 – Related formulation claim, expires May 13, 2040
  • US12214017/US8129343B2 – Additional composition/use patents, expiring 2038‑2041
These extended protections help delay generic competition in major markets such as the U.S. until the late 2030s–early 2040s.
Frequently Asked Questions
What is Semaglutide and how does it work?
Semaglutide is a GLP-1 receptor agonist that mimics the natural hormone GLP-1. It helps regulate appetite and blood sugar levels by stimulating insulin secretion and inhibiting glucagon release.
What are the main clinical uses of Semaglutide?
It is commonly used in clinical research and treatments for type 2 diabetes management, weight management, and various obesity-related studies.
How is Semaglutide administered?
Semaglutide is administered via a once-weekly subcutaneous injection.
What is the typical dosage for weight management?
Common dosing protocols range from 0.25 mg up to 2.4 mg weekly, with gradual titration. A higher 7.2 mg weekly dose has also been approved in some regions to enhance weight-loss efficacy.
When do the key U.S. patents for Semaglutide expire?
The key U.S. patents covering its compositions, formulations, and therapeutic uses are set to expire between the late 2030s and early 2040s (specifically 2038 to 2041).

Related Products